Soon to be revealed: latest EMA thinking on trial data disclosure
This article was originally published in SRA
Executive Summary
In just over two weeks' time we will have a better idea of how the European Medicines Agency plans to implement its decision on the proactive publication of clinical trial data on authorized drugs, when it releases the recommendations of the five advisory groups set up following last year's workshop on trial data and transparency1.